DRUGS FOR SYMPTOMATIC TREATMENT OF HUNTINGTON'S DISEASE: A NEURODEGENERATIVE DISORDER
Journal Title: Journal of Biomedical and Pharmaceutical Research - Year 2013, Vol 2, Issue 6
Abstract
Huntington’s disease is a devastating inherited neurodegenerative disease characterized by progressive motor, cognitive, and psychiatric symptoms. Patients may present with any of these symptoms, and familiarity with the phenotype is therefore important. Chorea and loss of balance are early symptoms that patients notice, although families often notice cognitive or personality changes before this. Although no therapy is currently available to delay the onset of symptoms or prevent the progression of the disease, symptomatic treatment of patients with Huntington disease (HD) may improve the quality of life and prevent complications. As is the case with other neurological diseases, HD makes individuals more vulnerable to side effects from medications, particularly cognitive adverse effects. Symptomatic treatment for HD can be divided into drugs to treat the movement disorder and drugs to treat psychiatric or behavioral problems. Symptomatic treatment of Huntington’s disease involves use of Dopamine antagonists, presynaptic dopamine depleters, Antidepressants, Tranquillizers, Anxiolytic Benzodiazepines, Anticonvulsants and Antibiotics. Several medications including baclofen, idebenone and vitamin E have studied in clinical trials with limited samples. This article reviews current therapeutic agents for treatment of the symptoms of Huntington’s disease. The aim of present article is to provide in depth knowledge about symptomatic treatment and other therapies involved in the management of Huntington’s disease.
Authors and Affiliations
Pranab Prakash Panigrahi*| Executive, QC (Stability), Aurobindo Pharma Ltd., Mahaboob Nagar, Andhra Pradesh, India-509302
Keywords
Related Articles
- EP ID EP2352
- DOI -
- Views 368
- Downloads 22
GENOTYPIC AND BIOCHEMICAL CHARACTERIZATION OF PASTEURELLA MULTOCIDA ISOLATED FROM SHEEP AT SLAUGHTER IN AMMAN-JORDAN
Pasteurella multocida (p.m.) is a gram negative coccobacilli bacterial pathogen, classified into three subspecies, five capsular serogroups, which is the causative agent of a range of diseases in domestic animals of econ...
DESIGN AND DEVELOPMENT OF EUDRAGIT COATED CHITOSAN MICROSPHERES FOR COLON TARGETED DELIVERY
Oral route is the most convenient and preferred route but other routes for CDDS may be used. Rectal administration offers the shortest route for targeting drugs to the colon. However, reaching the proximal part of colo...
NUTRITIONAL PROBLEM IN MANDSAUR (M.P.)
Malnourishment and starvation has taken its toll twice on Subash Bheel (a resident of Hingua village, in Badwani district in Madhya Pradesh) who lost 2 of his children (Rakesh and Gaurav) in the last two months. Subhash...
Formulation and In-Vitro Evaluation of Immediate Release Tablets of Losartan Potassium Using Different Superdisintegrants
In the present study an attempt has been made to prepare the various trails (T1 to T7) of immediate release tablets of losartan potassium by using a suitable diluent (Microcrystalline cellulose PH 101), a binder (Pregel...
Transdermal Delivery of Bisoprolol Hemifumarate
The aim of this study was to formulate and evaluate the administration of bisoprolol hemifumarate (BH) using transdermal delivery systems. The following formulae were prepared as a reservoir to be used in batch formula...